Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity by Yaribeygi, Habib et al.
1 
Molecular Mechanisms by which GLP-1 RA and DPP-4i Induce 
Insulin Sensitivity
Running Title: GLP-1RA and Insulin Resistance  
Habib Yaribeygi1*, Thozhukat Sathyapalan2, Amirhossein Sahebkar3,4,5* 
1Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran 
2Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, 
University of Hull 
3Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University 
of Medical Sciences, Mashhad, Iran 
4Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, 
Mashhad, 
 Iran 
5School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, 
*Corresponding Author
Amirhossein Sahebkar, Biotechnology Research Center, Mashhad University of Medical Sciences, 
Mashhad 9177948564, Iran. Tel: +985138002299; Fax: +985138002287; E-mail: 
sahebkara@mums.ac.ir; amir_saheb2000@yahoo.com 




Glucagon-like peptide-1 is a peptide of incretin family which is used in the management of 
diabetes as glucagon-like peptide-1 receptor agonist (GLP-1RA). Dipeptidyl peptidase-4 
enzyme metabolizes glucagon-like peptide-1 and various dipeptidyl peptidase-4 enzyme 
inhibitors (DPP-4i) are also used in the management of diabetes. These antidiabetic agents 
provide anti-hyperglycemic effects via several molecular mechanisms including promoting 
insulin secretion, suppression of glucagon secretion and slowing the gastric emptying. There 
is some research suggesting that they can induce insulin sensitivity in peripheral tissues. In this 
study, we review the possible molecular mechanisms by which GLP-1RA and DPP-4i can 
improve insulin resistance and increase insulin sensitivity in insulin-dependent peripheral 
tissues.  
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The incidence of diabetes mellitus (DM) is increasing worldwide in an epidemic proportion 
[1]. This chronic disorder affects several metabolic pathways resulting in the production of 
various toxic byproducts leading to various complications of diabetes [2-4]. DM acts as a potent 
upstream event for many pathophysiologic pathways including oxidative stress, inflammation, 
fibrosis, apoptotic processes, TLR (toll-like receptor) activation, necrotic events and the 
activity of death receptors thereby inducing various forms of tissue dysfunction and diabetic 
complications [4-6]. Inadequate response to circulatory insulin, which is known as insulin 
resistance, play significant roles in the onset and progress of these pathologic pathways [7-9]. 
Therefore, different classes of antidiabetic medicines have been developed to increase the 
tissue sensitivity to insulin and normalize the glycemia thereby preventing the 
pathophysiologic mechanisms involved in diabetic complications [10-12]. 
Glucagon-like peptide receptor-1 agonists (GLP-1RA) is one of the classes of antidiabetic 
medications which provide anti-hyperglycemic effects via several molecular mechanisms [13]. 
These pharmacologic agents exert their pleiotropic effects by lowering postprandial 
hyperglycemia mainly via binding to their specific receptors in various tissues [13]. They have 
a lower risk of hypoglycemia due to their glucose-dependent mode of action [14, 15]. 
Dipeptidyl peptidase-4 inhibitors (DPP-4i) are another group of antidiabetic agents which work 
by inhibition of GLP-1 breakdown thereby increasing its bioavailability [13]. There is some 
evidence suggesting that they also can increase insulin sensitivity in insulin-dependent 
peripheral tissues [16-18]. In the current review, we present the possible molecular mechanisms 
by which GLP-1RA modulate insulin sensitivity in patients with diabetes. It must be noted that 
higher levels of GLP-1 modulate glucose homeostasis by several mechanisms including 
slowing gastric emptying, inhibiting gluconeogenesis and suppression of appetite [19, 20]. In 
this review, we focus on its insulin-sensitizing effects.   




Classification of Diabetes Mellitus   
Type 1 (T1DM) and type 2 diabetes (T2DM) are the two common forms of diabetes [21]. 
(T1DM accounts for about 5-10% of all patients with diabetes and  mainly results from beta-
cell dysfunction, reduction in insulin release and lower circulatory levels of insulin [21]. Type 
2 diabetes (T2DM) is the most prevalent form of diabetes which account for more than 90% of 
patients with diabetes [21]. T2DM mainly results from an inadequate cellular response to 
insulin (insulin resistance) in insulin-dependent peripheral tissues in addition of beta-cell 
dysfunction and other pathophysiological defects [21]. Gestational diabetes is another type of 
DM which occurs in pregnant women likely due to hormonal variations during pregnancy 
period and insulin resistance  [22]. Other forms of diabetes are latent autoimmune diabetes in 
adults or LADA, maturity-onset diabetes of the young (MODY), secondary diabetes to various 
conditions such as pancreatitis and secondary to various medications such as corticosteroids 
[23].  
Glucose Homeostasis and Insulin Signaling   
Glucose is a hexose carbohydrate and the preferred metabolic substrate for many types of 
human cells. It is a hydrophilic molecule with a molecular weight of 180 and thereby, is too 
big for easily passing across the cellular membrane [24, 25]. The two major pathways for 
glucose to enter cells are via active transporters (by sodium-glucose cotransporters  or SGLTs) 
or via specific carriers (by glucose transporters or GLUT) [25]. GLUTs are a family of proteins 
that provide bidirectional facilitated glucose transport across the cell membrane without 
consuming energy and are based on the glucose concentration gradient across the cell 
membrane [25, 26]. These are at least 14 different GLUT proteins in human of which  GLUT1-
4 are more important in glucose homeostasis [25, 27]. GLUT-4 works completely dependent 
on insulin hormone [25, 28]. It remains in the cytoplasmic vesicles in non-active forms and 
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activates in response to insulin and translocate into the specific cell membrane and thereby 
facilitates glucose entering into the adipocytes, cardiac and skeletal muscle cells [25, 27]. Since 
striated muscle tissues act as a storage for glucose as glycogen, GLUT-4 plays an important 
role in the whole-body glucose homeostasis [27].   
Insulin is an important metabolic hormone made up of 51 amino acids and has a molecular 
weight of 5808D. It belongs to a family of peptides which includes insulin-like growth factors 
(IGF) I and II, relaxin and some other insulin-like peptides [29, 30]. It has two distinct chains 
known as α and β. These chains are linked together by two disulfide bridges and a third one 
which is within the α chain [29, 30]. Insulin is secreted by pancreatic beta-cells when glucose 
enters into the islets via specific glucose carriers known as GLUT-2 by facilitated diffusion in 
responses to various stimuli such as higher plasma levels of glucose and amino acids [29, 30].   
Glucose is phosphorylated to G6P (glucose-6-phosphate) within the beta-cells [31]. This 
process is catalyzed by the glucokinase enzyme activity which acts as "glucose sensor" into the 
islets and thereby controls the rate of glucose entering into the islets and in turn the rate of 
insulin release [31]. G6P increases the ATP (adenosine triphosphate) to ADP (adenosine 
diphosphate) ratio in the beta-cells which in turns closes the ATP-sensitive K+ channels, 
depolarizes beta-cell membrane and augments the intracellular calcium levels by opening the 
voltage-dependent Ca2+ channels in the pancreatic beta-cells [31]. Increasing the intracellular 
Ca2+ levels induces the exocytosis of secretory granules containing insulin/proinsulin 
molecules from the beta-cells into the circulation [31].              
Insulin facilitates the glucose entering into the adipocytes, cardiac and skeletal muscle cells by 
sequential steps known as insulin signal transduction (IST) [32]. IST is initiated by binding the 
insulin to the α chain of specific receptors known as insulin receptors (IRs). IR is a member of 
transmembrane tyrosine kinases composed of α and β which is activated by insulin as well as 
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by IGF1 1 and 2 [32]. This process induces structural changes in β chain domain by prompting 
the auto-phosphorylation of tyrosine residues followed by downstream events such as the 
recruitment of different adaptor proteins i.e. insulin receptor substrates (IRSs), Shc2 protein, 
and APS protein3 [25, 33]. These processes provide an appropriate binding site for the IRS-14 
[33]. IRS-1 can be also activated by other kinases including ERK1/25, atypical PKC6, S6K17, 
SIK28, AKT, mTOR9 and ROCK110 as well as other types of kinases such as AMPK11 and 
GSK312 [33, 34]. Activated IRS-1 binds to PI3K13 and activate it which in turn catalyzes the 
conversion of PIP2 14 to PIP3 15 [35]. PIP3 is itself a potent activator for PKB (protein kinase B 
also known as Akt) [35]. Akt is final effector in this pathway which facilitates glucose entering 
into the cells by localization of GLUT-4 and inhibiting the glycogen synthase kinase leading 
to more glycogen synthesis [30, 35]. The complicated process of IST and insulin sensitivity 
can be modulated in all the above steps [36-38].  
GLP-1 Receptor Agonists and DPP-4 Inhibitors  
The glucagon-like peptide (GLP) is a protein belonging to the incretin family which is secreted 
from the intestine in response to food ingestion and stimulates the GLP-1 receptor (GLP-1R) 
[39]. The GLP-1R is a G-protein coupled protein mainly found in the pancreatic beta-cells and 
is involved in regulating the blood glucose in several ways [40]. It composed of two domains, 
                                                           
1 Insulin-like growth factor  
2 SHC-transforming  
3 adapter protein with a PH and SH2 domain  
4 insulin receptor substrate type 1  
5 extracellular signal‐regulated kinase 1/2  
6 protein kinase C 
7 Ribosomal protein S6 kinase beta-1  
8 serine/threonine-protein kinase 2 
9 mammalian target of rapamycin  
10 Rho-associated protein kinase 1  
11 AMP-activated protein kinase  
12 Glycogen synthase kinase 3  
13 phosphoinositide 3-kinase 
14 Phosphatidylinositol 4,5-bisphosphate  
15 Phosphatidylinositol 3,4,5-trisphosphate  
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the extracellular domain binds the C-terminal helix of GLP-1 and the transmembrane domain 
binds to the N-terminal region of GLP-1 [41-44].  
GLP-1 RA is a family of antidiabetic agents that mimic the effects of incretin hormone [45-
47]. Incretin is a family of metabolic hormones including GLP-1 and GIP (gastric inhibitory 
peptide), which decrease postprandial blood glucose by inhibition of glucagon secretion from 
pancreatic α-cells and inducing insulin release from β-cell in a blood glucose-dependent 
manner [46, 48, 49]. GLP-1RA have additional effects such as delaying the gastric emptying, 
appetite suppression, declining nutrient absorption in the gut, improvement of lipid 
metabolism, inhibition of pancreatic β-cell apoptosis and induction of beta-cell neogenesis [48, 
50, 51].  
Table 1. Two main classes of antidiabetic drugs which work by GLP-1 level   
Classes of 
Antidiabetic Drug Approved Forms  
Mechanisms of Hypoglycemic 






Mimic the hypoglycemic effects 
of incretin such as insulin 
secretion, glucagon release 
suppression, appetite inhibition, 




Vildagliptin, Linagliptin  
Block the GLP-1 deactivator 
enzyme (DPP-4 enzyme) 
leading to enhanced 
hypoglycemic effects of native 
GLP-1   
[52, 53] 
 
Dipeptidyl peptidase-4 inhibitor (DPP-4i) are another type of antidiabetic agents with similar 
hypoglycemic effects to GLP-1RA. They act by preventing the inactivation of GLP-1 thereby 
increasing the active levels of native GLP-1 [52, 53]. After posttranslational processes of pre-
glucagon (PG) peptides in intestinal L cells, at least four separate forms of PG produced that 
are all can be inactivated by DPP-4 enzyme by removing the two amino acids from N-terminal 
residue [54]. DPP-4 is mainly located on the surface of the most types of cells including the 
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endothelial cells, renal epithelial cells and T lymphoid cells, where they have a binding partner 
element which makes intracellular signals [55].  
 
GLP-1 and Insulin Sensitivity   
In addition to the aforementioned hypoglycemic effects, there is strong evidence indicating 
GLP-1 increases insulin sensitivity in peripheral tissues [17, 19] (fig 1). The higher levels of 
GLP-1, by either GLP-1RA and/or DPP-4i administration, can induce peripheral insulin 
sensitivity through several direct or indirect molecular pathways [17, 18, 56]. In the following 
paragraphs, we discuss the possible molecular mechanisms involved in the GLP-1 dependent 
insulin sensitivity.  
Figure 1: Possible molecular mechanisms by which GLP-1 induces insulin sensitivity  
 
1. GLP-1 and Insulin Secretion  
GLP-1 receptors analogues and/or its breakdown enzyme inhibitors are known stimulators for 
pancreatic beta cells to secrete postprandial insulin in response to higher levels of blood glucose 
in a concentration-dependent manner [57]. It has suggested that GLP-1 induces insulin 
secretion through several molecular pathways such as cAMP production, Ca2+ dependent 
voltage-gated channels, proinsulin granule recruitment and promoting vesicle ducking [57]. 
There is also evidence that DPP-4i can stimulate insulin release  [58]. Consequently, GLP-1 
based therapies are now routinely used in clinical practice for the treatment of T2DM and 
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obesity [57, 59, 60]. This islet cell stimulating effect of GLP-1 could be one of the therapeutic 
targets even in some cases of T1DM and/or T2DM with dysfunctional beta-cells [57, 61, 62].  
2. GLP-1 and Oxidative Stress 
Oxidative stress has pivotal roles in the pathophysiology of many complications of diabetes as 
well as insulin resistance [63-65]. The free radical overload reduces the insulin sensitivity and 
induces insulin resistance by several molecular pathways including IKKβ16/NF‐κB17 and 
JNK18 pathways, IRS degradation, GLUT-4 down-regulation, lowering the insulin-dependent 
IRS‐1 and PIP‐kinase transfer between cytoplasm and microsomes [65-68]. Hence, readjusting 
the redox state in favor of physiologic milieu with a balance between free radicals and 
antioxidative elements is an attractive goal for designing novel antidiabetic agents [11, 69, 70].   
On the other hand, emerging evidence suggests that GLP-1 receptor induction by either GLP-
1RA and /r DPP-4i can result in improved antioxidative outcomes [39, 71, 72]. Oh and 
colleagues in 2017 suggested that GLP-1 have antioxidative potentials either by the glucose-
lowering effects or via Nrf219 signaling pathways and potentiation of antioxidant defense 
system [39, 73]. The inducers of Nrf2 signaling pathways improves insulin sensitivity in 
diabetic milieu [74, 75]. Deng and coworkers in 2018 showed that GLP-1 can induce Nrf2 
signaling pathways and increases the expression of antioxidant elements in the neuronal cells 
[73]. Fernández-Millán and coworkers in 2016 found that GLP-1 directly increases Nrf2 
signaling and improves oxidative stress in the pancreatic beta-cells [76]. Also, Puddu et al in 
2013 provided further data suggesting GLP-1 attenuated the oxidative stress by suppressing 
AGE20-RAGE21 interaction in the diabetic milieu [77]. Moreover, Tomas et al in 2011 
                                                           
16 inhibitor of nuclear factor kappa-B kinase subunit beta  
17 nuclear factor kappa-B  
18 c-Jun N-terminal kinase  
19 Nuclear factor erythroid 2-related factor 2  
20 Advanced glycation end product  
21 Receptors for AGE  
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discovered a nano-peptide derived from GLP-1 which reduces the oxidative stress via 
mitochondria-dependent mechanism [78]. Patel et al in 2013 demonstrated that GLP-1 
improves insulin sensitivity by attenuating the oxidative stress in diabetic mice [79]. Okada et 
al in 2014 and Rizzo et al in 2015 provided clinical evidence indicating liraglutide decreased 
the oxidative stress in patients with T2DM [80, 81]. This evidence strongly suggested that 
GLP-1 can induce insulin sensitivity by ameliorating oxidative stress [77-81].  
3. GLP-1 and Inflammatory responses 
Inflammatory processes have pivotal roles in the pathophysiology of insulin resistance [65, 
82]. These biologic events can impair IST via several molecular mechanisms including 
IKKβ/NF‐κB and JNK22 pathway activation, serine phosphorylation of IRS‐1 in the site of 307, 
GLUT‐4 and IRS‐1 down-regulation as well as IRS-1 degradation [65, 83-85]. Hence, 
ameliorating the inflammation is one of the ideal therapeutic targets for antidiabetic medicines 
[10, 12]. There is strong evidence indicating GLP-1 has potent anti-inflammatory potentials 
which may be beneficial against inflammatory responses and reduces the circulating 
inflammatory mediators leading to an increase in peripheral insulin sensitivity [12, 86-91]. 
Kodera et al in 2011 demonstrated that exendin-4, of the GLP-1RA, directly reduced 
inflammatory mediators such as ICAM (intercellular adhesion molecule-1), type IV collagen, 
and Nf-κb activation as well as reduced macrophage infiltration [91]. Also, Shiraki and 
coworkers in 2012 reported that GLP-1 attenuated inflammatory responses via lowering the 
TNF-α and Nf-κb expression levels in the umbilical endothelial cells [90]. Krasner et al in 2014 
reported similar findings implying GLP-1 reduces inflammatory responses by calcium and 
AMPK dependent molecular pathways [87].  
                                                           
22 c-Jun N-terminal kinase  
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Guo and colleagues in 2016 found that exendin-4 improved insulin sensitivity by lowering the 
inflammatory responses [17]. They demonstrated that it markedly reduced macrophage-derived 
insulin resistance by Nf-κb dependent molecular pathway leading to lower inflammation-
induced insulin resistance [17]. Also, Zheng et al in 2018 revealed that raising the levels of 
GLP-1 by DPP-4i improved insulin sensitivity by ameliorating the inflammatory responses via 
AMPK/mTOR molecular mechanisms in the diabetic animals [92]. Zhuge and coworkers in 
2016 provided data indicating linagliptin improved insulin sensitivity by modulating 
macrophage-dependent inflammatory events [93]. These evidence suggest that GLP-1 can 
promote insulin sensitivity by a reduction in inflammatory responses [17, 92, 93].    
4. GLUT-4 Expression and Glucose Transport  
The GLUT-4 is insulin-dependent glucose carrier and any disruption of its function will result 
in insulin resistance [94, 95]. There is some evidence that GLP-1 induces glucose transport 
across the cell membrane [96-98] and also induce GLUT-4 expression [99, 100]. Wang et al in 
1997 demonstrated that GLP-1 increases GLUT-4 expression and glucose transport in 
adipocytes [100]. Villanueva-Peñacarrillo et al in 2001 reported that GLP-1 up-regulated the 
GLUT-4 expression at both mRNA and protein levels in adipocytes and muscle tissues of 
diabetic animals [99]. Also, Green and coworkers in 2012 observed that GLP-1 increased the 
GLUT-4 expression at the protein level by PI3-K dependent mechanism in human satellite cells 
[101]. Moreover, Andreozzi and coworkers in 2016 found that GLP-1 increased glucose 
transport across skeletal muscle cells via up-regulating the GLUT-4 by an AMPK-dependent 
manner [102]. Similarly, Li et al in 2014 demonstrated that liraglutide induces GLUT-4 
translocation/expression by AMPK dependent mechanisms in skeletal muscles of diabetic mice 
[103]. Giannocco et al in 2013 provided similar data for DPP-4i indicating sitagliptin increased 
GLUT-4 translocation in the heart and skeletal muscle of rats [104]. This evidence strongly 
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suggests that GLP-1 can improve insulin sensitivity by GLUT-4 expression/translocation [101-
104].     
5. GLP-1 and Plasma Lipids' Profile 
The plasma lipid profile affects insulin sensitivity [105, 106]. Emerging evidence has 
demonstrated the molecular relationships between lipid profile and dysfunctional lipid 
metabolism with varying degrees of insulin resistance indicating an optimum profile of plasma 
lipid is needed for physiological insulin sensitivity in peripheral tissues [106]. Higher levels of 
adipocytes and lipids/lipoproteins (e.g. cholesterol, triglycerides, HDL, VLDL and LDL), 
initiate molecular mechanisms that have a negative effect on insulin sensitivity [106-109].  
GLP-1 can potentially modulate lipid metabolism and correct dyslipidemia through various 
molecular mechanisms and through activating different mediators and metabolic enzymes 
[110-112]. They can potentially modulate some microRNAs (miR) involved in lipid 
metabolism such as miR-200b, miR-200c, miR-34a, miR-338 and miR-21 [113-116]. 
Therefore, recent evidence suggested these hypoglycemic medications are promising 
therapeutic agents for dyslipidemia-induced disorders such as NAFLD (non-alcoholic fatty 
liver disease) and atherosclerosis in the diabetic milieu [117-120]. Ejarque et al in 2019 
demonstrated that GLP-1 expressed on adipocytes regulates the adipose tissue metabolism 
leading to higher insulin sensitivity [121]. Also, Parlevliet and coworkers in 2012 found that 
GLP-1 receptor agonist, exendin-4, improved insulin sensitivity by regulating the VLDL 
production in diabetic mice [122]. Moreover, Cani et al in 2006 suggested that lipid-lowering 
and insulin-sensitizing effects of oligofructose are mediated via GLP-1 receptors in mice with 
T1DM [123]. There is a similar finding of the role of DPP-4i [124-126]. Baumeier et al in 2017 
reported that higher expression levels of DPP-4i improved insulin sensitivity by readjusting the 
lipid metabolism [124]. Also, Silva and colleagues in 2019 showed that DPP-4i activity is 
correlated to the improvement of lipid metabolism and an increase in insulin sensitivity in 
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patients with T2DM [125]. This evidence strongly suggested that GLP-1 can improve insulin 
sensitivity by controlling lipid metabolism and thereby improving dyslipidemia, however, 
more clinical studies are still needed.     
6. GLP-1 and Insulin Signaling Pathways  
The GLP-1 amplifies IST in various steps [127]. Wang et al in 1997 demonstrated that GLP-1 
analogues improved insulin signaling in 3T3-L1 adipocytes [100]. Gao et al in 2007 provided 
evidence suggesting GLP-1 induce insulin signaling pathways by up-regulation of 
phosphorylated IR-β, IRS-1, Akt and GSK-3beta (glycogen synthase kinase 3 beta) in 
adipocytes leading to more insulin sensitivity [127]. Kawamori and coworkers in 2017 reported 
that GLP-1 signaling compensated IST impairment in the diabetic milieu and improved it 
[128]. They found that GLP-1 promoted Akt phosphorylation and protein expression of cyclins 
A, D1 and E leading to improved IST in adipocytes [128]. This evidence strongly suggested 
that GLP-1 has potent effects on insulin signaling pathways and thereby induces insulin 
sensitivity at least partly via IST induction [100, 127, 128].       
7. GLP-1 and Beta-cell Function 
A healthy beta- cell with normal physiologic function is a key element for appropriate insulin 
sensitivity [129, 130]. Many cases of DM are related to varying degrees of beta-cell 
dysfunction and thereby, reversing the pathophysiologic pathways involved in beta-cell 
dysfunction is an attractive target for the management of diabetes [131, 132]. There is some 
evidence indicating that GLP-1 can improve beta-cell function [133-136]. Tews et al in 2009 
demonstrated that exendin-4 prevents beta-cell apoptosis and improves islets' function in a 
diabetic milieu  [133]. Kawamori et al in 2017 showed that GLP-1 signaling induced beta-cell 
proliferation in adipocytes [128]. Caporarello and coworkers in 2017 reported that GLP-1 
receptor agonists markedly enhanced pancreatic beta-cell generation in mice [137]. Also, Kim 
and colleagues in 2017 reported the same findings implying exendin-4 ameliorates beta-cell 
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damage and improves insulin sensitivity in rats [134]. Moreover, Shimoda et al in 2011 found 
that liraglutide promoted pancreatic beta-cell function in diabetic mice [135]. Gedulin et al in 
2005 reported that exendin-4 increases insulin sensitivity index and reduces blood glucose 
levels by increasing beta-cell mass in obese rats [136]. They showed that GLP-1 has trophic 
effects on pancreatic islets and exerts neogenesis and cell proliferation independent of glucose 
homeostasis and body weight [136, 138]. Other possible pathways are also suggested [139, 
140]. Hao et al in 2017 demonstrated that GLP-1 increases insulin sensitivity by improvement 
in beta-cell function through PDX-123/JAK signaling pathways [139]. Also, Zummo and 
coworkers in 2017 found that GLP-1 protects pancreatic beta-cell function by readjusting the 
autophagy/lysosomal homeostasis in INS-1E β-cells [140]. Akarte and colleagues in 2012 
showed that DPP-4i (vidagliptin) increases beta-cell mass in the diabetic milieu [141]. This 
evidence suggest that improvement in beta-cell function is another pathway by which GLP-1 
induces insulin sensitivity [133-136] [139].     
8. GLP-1 and ER Stress 
Endoplasmic reticulum (ER) is one of the main organelles in eukaryotic cells which have 
significant roles in the cellular homeostasis [142]. Various pathophysiological states and 
pharmacologic agents disturb the functioning of ER resulting in ER stress. ER stress 
contributes to the development of diabetes complications [143, 144]. There is some evidence 
suggesting GLP-1 can potentially improve ER stress in diabetic milieu [18, 135, 145]. Jiang et 
al in 2018 demonstrated that GLP-1 improved insulin sensitivity by ameliorating ER stress 
through mTOR signaling dependent pathways and its downstream mechanisms in adipocytes 
[18]. Also, Shimoda et al in 2011 reported that liraglutide improved ER stress-induced insulin 
resistance in the diabetic mice [135]. Moreover, Shimizu et al in 2012 found that vildagliptin 
(DPP-4i) improved ER stress in beta-cells by down-regulating the C/EBPB protein (a 
                                                           
23 duodenal homeobox-1  
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transcription factor) in diabetic mice [145].  This evidence suggest that GLP-1 can modulate 
ER stress-induced insulin resistance [18, 135, 145].  
 
Table 2. Possible insulin sensitizer influences of GLP-1 (Nrf2= Nuclear factor erythroid 2-related factor 
2; HO-1= heme oxigenase-1; AGE= Advanced glycation end product; RAGE= receptor for AGE; Nf-
κb=nuclear factor kappa b; IRS-1=insulin receptor substrate-1; ER=endoplasmic reticulum; mTOR= 
mammalian target of rapamycin; C/EBPB= a transcription factor)   
Molecular Mechanisms  Effects  Ref.  
Insulin Secretion 
 Induces insulin expression/release via vary 
molecular mechanisms such as cAMP 
production, Ca2+ dependent voltage-gated 
channels, proinsulin granule recruitment and 
promoting vesicle ducking  
[57, 59, 60] 
Oxidative Stress  
Attenuates oxidative stress by several 
molecular pathways such as Nrf2, HO-1 and 
AGE-RAGE interactions, reduces the free 
radical generation   
[39, 73, 77-81] 
Inflammatory 
Responses  
Ameliorates inflammation-induced insulin 
resistance via lowering the pro-inflammatory 
mediators as Nf-κb, ICAM-1, TNF-α and 
signaling pathways such as AMPK/mTOR   
[17, 92, 93] 
GLUT-4 
Expression/Localization  
Increase GLUT-4 expression/localization in 
insulin-dependent tissues  [101-104]  
Lipid Metabolism  
Improve plasma lipid profile leading to a 




Improve pancreatic beta-cell function via 
several molecular pathways as neogenesis 
induction and apoptosis inhibition   
[133-136]  
Insulin Signal 
Transduction   
Amplify insulin signal transduction at various 
steps such as Akt and IRS-1 phosphorylation   [100, 127, 128] 
ER Stress  
Attenuate ER stress thru mTOR signaling or 
down-regulating the C/EBPB protein and 
thereby decline ER stress-induced insulin 
resistance  
[18, 135, 145]  
 
Other potential molecular pathways  
In addition to the above described molecular pathways, some other molecular mechanisms may 
be involved in GLP-1 dependent inulin sensitivity [88][146]. GLP-1 potentially suppress 
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glucagon secretion which can lead to higher insulin sensitivity [146, 147]. Also, there is 
evidence suggesting GLP-1 can stimulate the expression and release of adipokines and 
adiponectin which have major roles in the insulin signaling pathways [88]. They can also 
potentially modulate the mitochondrial function and improves insulin resistance due to 
mitochondrial dysfunctions [148].  
Conclusion  
GLP-1 is one of the main peptides of the incretin family which modulates glucose homeostasis 
through several molecular pathways. The two GLP-1 pathways based therapies for the 
treatment of T2DM are GLP-1 receptor agonists and DPP-4 inhibitors. They act as anti-
hyperglycemic agents through a variety of mechanisms including glucose dependent 
stimulation of insulin secretion, suppression of glucagon secretion, reduction of hepatic 
glucose output and suppression of appetite. These agents also increase insulin sensitivity via at 
least eight molecular pathways including oxidative stress, inflammation, ER stress, lipid 





The authors are thankful to the "Research center of physiology, Semnan University of medical 
sciences (Semnan, Iran)" for providing technical supports. 
Conflict of Interests  
The authors declare that they have no conflict of interest in this study.  
 
  




1. Ogurtsova, K., et al., IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 
2015 and 2040. Diabetes research and clinical practice, 2017. 128: p. 40-50. 
2. Forbes, J.M. and M.E. Cooper, Mechanisms of diabetic complications. Physiological reviews, 
2013. 93(1): p. 137-188. 
3. Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. diabetes, 
2005. 54(6): p. 1615-1625. 
4. Volpe, C.M.O., et al., Cellular death, reactive oxygen species (ROS) and diabetic complications. 
Cell death & disease, 2018. 9(2): p. 119. 
5. Buraczynska, M., et al., The effect of Toll-like receptor 4 gene polymorphism on vascular 
complications in type 2 diabetes patients. Diabetes research and clinical practice, 2016. 116: 
p. 7-13. 
6. Mattisson, I.Y., et al., Elevated markers of death receptor-activated apoptosis are associated 
with increased risk for development of diabetes and cardiovascular disease. EBioMedicine, 
2017. 26: p. 187-197. 
7. Jia, G., V.G. DeMarco, and J.R. Sowers, Insulin resistance and hyperinsulinaemia in diabetic 
cardiomyopathy. Nature Reviews Endocrinology, 2016. 12(3): p. 144. 
8. Pop, A., et al., Insulin resistance is associated with all chronic complications in type 1 diabetes: 
在 1 型糖尿病中胰岛素抵抗与所有的慢性并发症都相关. Journal of diabetes, 2016. 8(2): p. 
220-228. 
9. Patel, T.P., et al., Insulin resistance: an additional risk factor in the pathogenesis of 
cardiovascular disease in type 2 diabetes. Heart failure reviews, 2016. 21(1): p. 11-23. 
10. Yaribeygi, H., et al., Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus 
on diabetic kidneys. Drug discovery today, 2018. 
11. Yaribeygi, H., et al., Antioxidative potential of antidiabetic agents: A possible protective 
mechanism against vascular complications in diabetic patients. Journal of cellular physiology, 
2019. 234(3): p. 2436-2446. 
12. Yaribeygi, H., et al., A review of the anti-inflammatory properties of antidiabetic agents 
providing protective effects against vascular complications in diabetes. Journal of cellular 
physiology, 2019. 234(6): p. 8286-8294. 
13. DeFronzo, R.A., Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. 
Diabetes, Obesity and Metabolism, 2017. 19(10): p. 1353-1362. 
14. Trujillo, J.M., W. Nuffer, and S.L. Ellis, GLP-1 receptor agonists: a review of head-to-head 
clinical studies. Therapeutic advances in endocrinology and metabolism, 2015. 6(1): p. 19-28. 
15. Prasad-Reddy, L. and D. Isaacs, A clinical review of GLP-1 receptor agonists: efficacy and safety 
in diabetes and beyond. Drugs in context, 2015. 4. 
16. Cabou, C., et al., Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and 
insulin sensitivity. Diabetes, 2008. 57(10): p. 2577-2587. 
17. Guo, C., et al., Glucagon-like peptide 1 improves insulin resistance in vitro through anti-
inflammation of macrophages. Brazilian Journal of Medical and Biological Research, 2016. 
49(12). 
18. Jiang, Y., et al., GLP-1 improves adipocyte insulin sensitivity following induction of endoplasmic 
reticulum stress. Frontiers in pharmacology, 2018. 9: p. 1168. 
19. Sandoval, D. and S.R. Sisley, Brain GLP-1 and insulin sensitivity. Molecular and cellular 
endocrinology, 2015. 418: p. 27-32. 
20. Marathe, C.S., et al., Effects of GLP-1 and incretin-based therapies on gastrointestinal motor 
function. Experimental diabetes research, 2011. 2011. 
21. Association, A.D., Diagnosis and classification of diabetes mellitus. Diabetes care, 2014. 
37(Supplement 1): p. S81-S90. 
22. de Faria Maraschin, J., Classification of diabetes, in Diabetes. 2013, Springer. p. 12-19. 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
18 
 
23. O’Neal, K.S., J.L. Johnson, and R.L. Panak, Recognizing and appropriately treating latent 
autoimmune diabetes in adults. Diabetes Spectrum, 2016. 29(4): p. 249-252. 
24. Gailliot, M.T. and R.F. Baumeister, The physiology of willpower: Linking blood glucose to self-
control, in Self-Regulation and Self-Control. 2018, Routledge. p. 137-180. 
25. Hall, J.E., Guyton and Hall textbook of medical physiology e-Book. 2015: Elsevier Health 
Sciences. 
26. Chen, Y. and J. Lippincott-Schwartz, Selective visualization of GLUT4 storage vesicles and 
associated Rab proteins using IRAP-pHluorin, in Rab GTPases. 2015, Springer. p. 173-179. 
27. Huang, S. and M.P. Czech, The GLUT4 glucose transporter. Cell metabolism, 2007. 5(4): p. 237-
252. 
28. Moraes-Vieira, P.M., A. Saghatelian, and B.B. Kahn, GLUT4 expression in adipocytes regulates 
de novo lipogenesis and levels of a novel class of lipids with antidiabetic and anti-inflammatory 
effects. Diabetes, 2016. 65(7): p. 1808-1815. 
29. Weiss, M., D.F. Steiner, and L.H. Philipson, Insulin biosynthesis, secretion, structure, and 
structure-activity relationships. 2014. 
30. Koeppen, B.M. and B.A. Stanton, Berne and levy physiology e-book. 2017: Elsevier Health 
Sciences. 
31. Rutter, G.A., et al., Pancreatic β-cell identity, glucose sensing and the control of insulin 
secretion. Biochem J, 2015. 466(2): p. 203-218. 
32. Færch, K., et al., Insulin resistance is accompanied by increased fasting glucagon and delayed 
glucagon suppression in individuals with normal and impaired glucose regulation. Diabetes, 
2016: p. db160240. 
33. Kiselyov, V.V., et al., Harmonic oscillator model of the insulin and IGF1 receptors’ allosteric 
binding and activation. Molecular systems biology, 2009. 5(1): p. 243. 
34. Copps, K. and M. White, Regulation of insulin sensitivity by serine/threonine phosphorylation 
of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia, 2012. 55(10): p. 2565-2582. 
35. Ho, C.K., G. Sriram, and K.M. Dipple, Insulin sensitivity predictions in individuals with obesity 
and type II diabetes mellitus using mathematical model of the insulin signal transduction 
pathway. Molecular genetics and metabolism, 2016. 119(3): p. 288-292. 
36. Wojtaszewski, J., et al., Insulin signaling and insulin sensitivity after exercise in human skeletal 
muscle. Diabetes, 2000. 49(3): p. 325-331. 
37. Pessin, J.E. and A.R. Saltiel, Signaling pathways in insulin action: molecular targets of insulin 
resistance. The Journal of clinical investigation, 2000. 106(2): p. 165-169. 
38. Chang, L., S.-H. Chiang, and A.R. Saltiel, Insulin signaling and the regulation of glucose 
transport. Molecular medicine, 2004. 10(7): p. 65. 
39. Oh, Y. and H.-S. Jun, Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. 
International journal of molecular sciences, 2017. 19(1): p. 26. 
40. Donnelly, D., The structure and function of the glucagon-like peptide-1 receptor and its ligands. 
British journal of pharmacology, 2012. 166(1): p. 27-41. 
41. Underwood, C.R., et al., Crystal structure of glucagon-like peptide-1 in complex with the 
extracellular domain of the glucagon-like peptide-1 receptor. Journal of Biological Chemistry, 
2010. 285(1): p. 723-730. 
42. Song, G., et al., Human GLP-1 receptor transmembrane domain structure in complex with 
allosteric modulators. Nature, 2017. 546(7657): p. 312. 
43. Brubaker, P. and D. Drucker, Structure-function of the glucagon receptor family of G protein-
coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors and Channels, 
2002. 8(3-4): p. 179-188. 
44. Wootten, D., et al., A hydrogen-bonded polar network in the core of the glucagon-like peptide-
1 receptor is a fulcrum for biased agonism: lessons from class B crystal structures. Molecular 
pharmacology, 2016. 89(3): p. 335-347. 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
19 
 
45. Yaribeygi, H., et al., A review of the anti-inflammatory properties of antidiabetic agents 
providing protective effects against vascular complications in diabetes. Journal of cellular 
physiology, 2018. 
46. Drucker, D.J. and M.A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists 
and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 2006. 368(9548): p. 1696-
1705. 
47. Islam, M., Insulinotropic Effect of Herbal Drugs for Management of Diabetes Mellitus: A 
Congregational Approach. Biosens J, 2016. 5(142): p. 2. 
48. Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. 
Nature Reviews Endocrinology, 2012. 8(12): p. 728. 
49. Baggio, L.L. and D.J. Drucker, Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007. 
132(6): p. 2131-2157. 
50. Scott, K.A. and T.H. Moran, The GLP-1 agonist exendin-4 reduces food intake in nonhuman 
primates through changes in meal size. American Journal of Physiology-Regulatory, Integrative 
and Comparative Physiology, 2007. 293(3): p. R983-R987. 
51. Ding, X., et al., Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic 
steatosis in ob/ob mice. Hepatology, 2006. 43(1): p. 173-181. 
52. Association, A.D., 2. Classification and diagnosis of diabetes: standards of medical care in 
diabetes—2018. Diabetes Care, 2018. 41(Supplement 1): p. S13-S27. 
53. Ahren, B., DPP-4 inhibitors. Best Practice & Research Clinical Endocrinology & Metabolism, 
2007. 21(4): p. 517-533. 
54. Brubaker, P.L., The Glucagon-Like Peptides. Annals of the New York Academy of Sciences, 
2006. 1070(1): p. 10-26. 
55. Sun, A.-l., et al., Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney 
disease. Diabetes and Vascular Disease Research, 2012. 9(4): p. 301-308. 
56. Parlevliet, E.T., et al., GLP-1 treatment reduces endogenous insulin resistance via activation of 
central GLP-1 receptors in mice fed a high-fat diet. American Journal of Physiology-
Endocrinology and Metabolism, 2010. 299(2): p. E318-E324. 
57. Meloni, A., et al., GLP-1 receptor activated insulin secretion from pancreatic β‐cells: 
mechanism and glucose dependence. Diabetes, Obesity and Metabolism, 2013. 15(1): p. 15-
27. 
58. Inaba, W., et al., Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor 
vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. European 
journal of pharmacology, 2012. 691(1-3): p. 297-306. 
59. Jones, B., et al., Control of insulin secretion by GLP-1. Peptides, 2018. 100: p. 75-84. 
60. Kirk, R.K., et al., Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-
1R) expression in the pancreas of patients with type 2 diabetes. Diabetes, Obesity and 
Metabolism, 2017. 19(5): p. 705-712. 
61. Carlessi, R., et al., GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-
dependent HIF-1α activation. Scientific reports, 2017. 7(1): p. 2661. 
62. Rowlands, J., et al., Pleiotropic Effects of GLP-1 and analogs on cell signaling, metabolism and 
function. Frontiers in endocrinology, 2018. 9: p. 672. 
63. Yaribeygi, H., et al., Oxidative stress induces renal failure: A review of possible molecular 
pathways. Journal of cellular biochemistry, 2018. 119(4): p. 2990-2998. 
64. Yaribeygi, H., S.L. Atkin, and A. Sahebkar, Mitochondrial dysfunction in diabetes and the 
regulatory roles of antidiabetic agents on the mitochondrial function. Journal of cellular 
physiology, 2019. 234(6): p. 8402-8410. 
65. Yaribeygi, H., et al., Insulin resistance: Review of the underlying molecular mechanisms. 
Journal of cellular physiology, 2019. 234(6): p. 8152-8161. 
66. Hurrle, S. and W.H. Hsu, The etiology of oxidative stress in insulin resistance. biomedical 
journal, 2017. 40(5): p. 257-262. 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
20 
 
67. Furukawa, S., et al., Increased oxidative stress in obesity and its impact on metabolic 
syndrome. The Journal of clinical investigation, 2017. 114(12): p. 1752-1761. 
68. Elmarakby, A.A. and J.C. Sullivan, Relationship between oxidative stress and inflammatory 
cytokines in diabetic nephropathy. Cardiovascular therapeutics, 2012. 30(1): p. 49-59. 
69. Yaribeygi, H., S.L. Atkin, and A. Sahebkar, A review of the molecular mechanisms of 
hyperglycemia-induced free radical generation leading to oxidative stress. Journal of cellular 
physiology, 2019. 234(2): p. 1300-1312. 
70. Yaribeygi, H., et al., Sodium–glucose cotransporter inhibitors and oxidative stress: An update. 
Journal of cellular physiology, 2019. 234(4): p. 3231-3237. 
71. Laviola, L., et al., Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of 
human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein 
kinase signaling pathway. Endocrinology, 2012. 153(12): p. 5770-5781. 
72. Cai, X., et al., GLP-1 treatment protects endothelial cells from oxidative stress-induced 
autophagy and endothelial dysfunction. International journal of biological sciences, 2018. 
14(12): p. 1696. 
73. Deng, C., et al., Liraglutide activates the Nrf2/HO-1 antioxidant pathway and protects brain 
nerve cells against cerebral ischemia in diabetic rats. Computational intelligence and 
neuroscience, 2018. 2018. 
74. Uruno, A., et al., The Keap1-Nrf2 system prevents onset of diabetes mellitus. Molecular and 
cellular biology, 2013. 33(15): p. 2996-3010. 
75. Holmström, K.M., et al., Nrf2 impacts cellular bioenergetics by controlling substrate 
availability for mitochondrial respiration. Biology open, 2013. 2(8): p. 761-770. 
76. Fernández-Millán, E., et al., Glucagon-like peptide-1 improves beta-cell antioxidant capacity 
via extracellular regulated kinases pathway and Nrf2 translocation. Free Radical Biology and 
Medicine, 2016. 95: p. 16-26. 
77. Puddu, A., et al., An emerging role of glucagon-like peptide-1 in preventing advanced-
glycation-end-product-mediated damages in diabetes. Mediators of inflammation, 2013. 
2013. 
78. Tomas, E., V. Stanojevic, and J.F. Habener, GLP-1-derived nonapeptide GLP-1 (28–36) amide 
targets to mitochondria and suppresses glucose production and oxidative stress in isolated 
mouse hepatocytes. Regulatory peptides, 2011. 167(2-3): p. 177-184. 
79. Patel, V., et al., Combination of omeprazole with GLP-1 agonist therapy improves insulin 
sensitivity and antioxidant activity in liver in type 1 diabetic mice. Pharmacological Reports, 
2013. 65(4): p. 927-936. 
80. Okada, K., et al., Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic 
peptide levels in patients with type 2 diabetes mellitus. Endocrine, 2014. 47(3): p. 962-964. 
81. Rizzo, M., et al., Liraglutide reduces oxidative stress and restores heme oxygenase-1 and 
ghrelin levels in patients with type 2 diabetes: a prospective pilot study. The journal of clinical 
endocrinology & metabolism, 2015. 100(2): p. 603-606. 
82. Yaribeygi, H., S.L. Atkin, and A. Sahebkar, Interleukin-18 and diabetic nephropathy: A review. 
Journal of cellular physiology, 2019. 234(5): p. 5674-5682. 
83. De Luca, C. and J.M. Olefsky, Inflammation and insulin resistance. FEBS letters, 2008. 582(1): 
p. 97-105. 
84. Fantuzzi, G., Adipose tissue, adipokines, and inflammation. Journal of Allergy and clinical 
immunology, 2005. 115(5): p. 911-919. 
85. Tilg, H. and A.R. Moschen, Inflammatory mechanisms in the regulation of insulin resistance. 
Molecular medicine, 2008. 14(3-4): p. 222-231. 
86. Hattori, Y., et al., RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, 
upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. 
Diabetologia, 2010. 53(10): p. 2256. 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
21 
 
87. Krasner, N.M., et al., Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial 
cell inflammation through a calcium and AMPK dependent mechanism. Plos one, 2014. 9(5): 
p. e97554. 
88. Hosaka, T., et al., Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression 
through protein kinase A pathway and prevents inflammatory adipokine expression. 
Biochemical and biophysical research communications, 2009. 390(3): p. 613-618. 
89. Lee, Y.-S. and H.-S. Jun, Anti-inflammatory effects of GLP-1-based therapies beyond glucose 
control. Mediators of inflammation, 2016. 2016. 
90. Shiraki, A., et al., The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced 
oxidative stress and inflammation in endothelial cells. Atherosclerosis, 2012. 221(2): p. 375-
382. 
91. Kodera, R., et al., Glucagon-like peptide-1 receptor agonist ameliorates renal injury through 
its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 
diabetes. Diabetologia, 2011. 54(4): p. 965-978. 
92. Zheng, W., et al., Dipeptidyl-peptidase 4 inhibitor sitagliptin ameliorates hepatic insulin 
resistance by modulating inflammation and autophagy in ob/ob mice. International journal of 
endocrinology, 2018. 2018. 
93. Zhuge, F., et al., DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and 
insulin resistance by regulating M1/M2 macrophage polarization. Diabetes, 2016. 65(10): p. 
2966-2979. 
94. Shan, W.-f., et al., Effects of GLUT4 expression on insulin resistance in patients with advanced 
liver cirrhosis. Journal of Zhejiang University SCIENCE B, 2011. 12(8): p. 677. 
95. Harriet Wallberg-Henriksson, J.R.Z., GLUT4: a key player regulating glucose homeostasis? 
Insights from transgenic and knockout mice. Molecular membrane biology, 2001. 18(3): p. 
205-211. 
96. Sancho, V., et al., Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose 
transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. Journal of 
molecular endocrinology, 2005. 35(1): p. 27-38. 
97. Sancho, V., et al., The action of GLP-1 and exendins upon glucose transport in normal human 
adipocytes, and on kinase activity as compared to morbidly obese patients. International 
journal of molecular medicine, 2007. 19(6): p. 961-966. 
98. Arnés, L., et al., Characteristics of GLP-1 and exendins action upon glucose transport and 
metabolism in type 2 diabetic rat skeletal muscle. International journal of molecular medicine, 
2008. 22(1): p. 127-132. 
99. Villanueva-Peñacarrillo, M.L., et al., Effect of GLP-1 treatment on GLUT2 and GLUT4 expression 
in type 1 and type 2 rat diabetic models. Endocrine, 2001. 15(2): p. 241-248. 
100. Wang, Y., et al., Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: 
glucagon-like peptide-1 and insulin interactions. Journal of molecular endocrinology, 1997. 
19(3): p. 241-248. 
101. Green, C.J., et al., Glucagon like peptide-1-induced glucose metabolism in differentiated 
human muscle satellite cells is attenuated by hyperglycemia. PloS one, 2012. 7(8): p. e44284. 
102. Andreozzi, F., et al., The GLP-1 receptor agonists exenatide and liraglutide activate Glucose 
transport by an AMPK-dependent mechanism. Journal of translational medicine, 2016. 14(1): 
p. 229. 
103. Li, Z., et al., Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-
activated protein kinase signaling pathways in mouse skeletal muscle cells. Metabolism, 2014. 
63(8): p. 1022-1030. 
104. Giannocco, G., et al., Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and 
expression in heart and skeletal muscle of spontaneously hypertensive rats. European journal 
of pharmacology, 2013. 698(1-3): p. 74-86. 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
22 
 
105. Zheng, S., et al., Associations of lipid profiles with insulin resistance and β cell function in adults 
with normal glucose tolerance and different categories of impaired glucose regulation. PloS 
one, 2017. 12(2): p. e0172221. 
106. Kawamoto, R., et al., Relationships between lipid profiles and metabolic syndrome, insulin 
resistance and serum high molecular adiponectin in Japanese community-dwelling adults. 
Lipids in health and disease, 2011. 10(1): p. 79. 
107. Kahn, S.E., R.L. Hull, and K.M. Utzschneider, Mechanisms linking obesity to insulin resistance 
and type 2 diabetes. Nature, 2006. 444(7121): p. 840. 
108. Polsky, S. and S.L. Ellis, Obesity, insulin resistance, and type 1 diabetes mellitus. Current 
Opinion in Endocrinology, Diabetes and Obesity, 2015. 22(4): p. 277-282. 
109. Tangvarasittichai, S., Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes 
mellitus. World journal of diabetes, 2015. 6(3): p. 456. 
110. Farr, S., J. Taher, and K. Adeli, Glucagon-like peptide-1 as a key regulator of lipid and 
lipoprotein metabolism in fasting and postprandial states. Cardiovascular & Haematological 
Disorders-Drug Targets (Formerly Current Drug Targets-Cardiovascular & Hematological 
Disorders), 2014. 14(2): p. 126-136. 
111. Lutz, T.A. and E. Osto, Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism. 
Current opinion in lipidology, 2016. 27(3): p. 257-263. 
112. J Patel, V., et al., Effect of GLP-1 based therapies on diabetic dyslipidemia. Current diabetes 
reviews, 2014. 10(4): p. 238-250. 
113. Shen, Y., et al., MicroRNA profile changes in liraglutide treated steatotic HepG2 cells. Int J Clin 
Exp Med, 2017. 10(3): p. 4856-4864. 
114. Capuani, B., et al., Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on 
GLP1 Action on miRNAs. Frontiers in endocrinology, 2018. 9. 
115. Guo, J., et al., Reduced miR-200b and miR-200c expression contributes to abnormal hepatic 
lipid accumulation by stimulating JUN expression and activating the transcription of srebp1. 
Oncotarget, 2016. 7(24): p. 36207. 
116. Wei, J., et al., MiR-338 controls BPA-triggered pancreatic islet insulin secretory dysfunction 
from compensation to decompensation by targeting Pdx-1. The FASEB Journal, 2017. 31(12): 
p. 5184-5195. 
117. Akaslan, S.B., et al., Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced 
obese rats. Metabolic syndrome and related disorders, 2013. 11(4): p. 243-250. 
118. Kato, H., et al., Effect of sitagliptin on intrahepatic lipid content and body fat in patients with 
type 2 diabetes. Diabetes research and clinical practice, 2015. 109(1): p. 199-205. 
119. Mulvihill, E.E., Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-
derived peptides glucagon like peptide 1 and glucagon like peptide 2. Current opinion in 
lipidology, 2018. 29(2): p. 95. 
120. Gastaldelli, A. and G. Marchesini, Time for Glucagon like peptide-1 receptor agonists treatment 
for patients with NAFLD? Journal of hepatology, 2016. 64(2): p. 262-264. 
121. Ejarque, M., et al., Role of adipose tissue GLP-1R expression in metabolic improvement after 
bariatric surgery in patients with type 2 diabetes. Scientific reports, 2019. 9(1): p. 6274. 
122. Parlevliet, E.T., et al., GLP-1 receptor activation inhibits VLDL production and reverses hepatic 
steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE* 3-Leiden mice. PloS one, 
2012. 7(11): p. e49152. 
123. Cani, P.D., et al., Improvement of glucose tolerance and hepatic insulin sensitivity by 
oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes, 2006. 55(5): p. 
1484-1490. 
124. Baumeier, C., et al., Elevated hepatic DPP4 activity promotes insulin resistance and non-
alcoholic fatty liver disease. Molecular metabolism, 2017. 6(10): p. 1254-1263. 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
23 
 
125. Silva Júnior, W.S., et al., Dipeptidyl Peptidase 4 Activity Is Related to Body Composition, 
Measures of Adiposity, and Insulin Resistance in Subjects with Excessive Adiposity and 
Different Degrees of Glucose Tolerance. Journal of diabetes research, 2019. 2019. 
126. Deacon, C.F., Physiology and pharmacology of DPP-4 in glucose homeostasis and the 
treatment of type 2 diabetes. Frontiers in endocrinology, 2019. 10: p. 80. 
127. Gao, H., et al., GLP-1 amplifies insulin signaling by up-regulation of IRβ, IRS-1 and Glut4 in 3T3-
L1 adipocytes. Endocrine, 2007. 32(1): p. 90-95. 
128. Kawamori, D., et al., GLP-1 signalling compensates for impaired insulin signalling in regulating 
beta cell proliferation in βIRKO mice. Diabetologia, 2017. 60(8): p. 1442-1453. 
129. Cernea, S. and M. Dobreanu, Diabetes and beta cell function: from mechanisms to evaluation 
and clinical implications. Biochemia medica: Biochemia medica, 2013. 23(3): p. 266-280. 
130. Maedler, K. and M. Donath, β-Cells in type 2 diabetes: a loss of function and mass. Hormone 
Research in Paediatrics, 2004. 62(Suppl. 3): p. 67-73. 
131. Page, K.A. and T. Reisman, Interventions to preserve beta-cell function in the management and 
prevention of type 2 diabetes. Current diabetes reports, 2013. 13(2): p. 252-260. 
132. Wajchenberg, B.L., Clinical approaches to preserve β-cell function in diabetes, in The Islets of 
Langerhans. 2010, Springer. p. 515-535. 
133. Tews, D., et al., Anti-apoptotic action of exendin-4 in INS-1 beta cells: comparative protein 
pattern analysis of isolated mitochondria. Hormone and metabolic research, 2009. 41(04): p. 
294-301. 
134. Kim, M.-H., et al., EX4 stabilizes and activates Nrf2 via PKCδ, contributing to the prevention of 
oxidative stress-induced pancreatic beta cell damage. Toxicology and applied pharmacology, 
2017. 315: p. 60-69. 
135. Shimoda, M., et al., The human glucagon-like peptide-1 analogue liraglutide preserves 
pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and 
endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia, 2011. 54(5): p. 1098-
1108. 
136. Gedulin, B.R., et al., Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in 
insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. 
Endocrinology, 2005. 146(4): p. 2069-2076. 
137. Caporarello, N., et al., Insulin receptor signaling and glucagon-like peptide 1 effects on 
pancreatic beta cells. PloS one, 2017. 12(8): p. e0181190. 
138. Buteau, J., GLP-1 signaling and the regulation of pancreatic β-cells mass/function. Avances en 
Diabetología, 2011. 27(1): p. 3-8. 
139. Hao, T., et al., Glucagon-like peptide 1 receptor agonist ameliorates the insulin resistance 
function of islet β cells via the activation of PDX-1/JAK signaling transduction in C57/BL6 mice 
with high-fat diet-induced diabetes. International journal of molecular medicine, 2017. 39(4): 
p. 1029-1036. 
140. Zummo, F.P., et al., Glucagon-like peptide 1 protects pancreatic β-cells from death by 
increasing autophagic flux and restoring lysosomal function. Diabetes, 2017. 66(5): p. 1272-
1285. 
141. Akarte, A.S., B. Srinivasan, and S. Gandhi, Vildagliptin selectively ameliorates GLP-1, GLUT4, 
SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose 
homeostasis in rats with streptozotocin-induced diabetes. Journal of Diabetes and its 
Complications, 2012. 26(4): p. 266-274. 
142. Ron, D. and P. Walter, Signal integration in the endoplasmic reticulum unfolded protein 
response. Nature reviews Molecular cell biology, 2007. 8(7): p. 519. 
143. Özcan, U., et al., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. 
Science, 2004. 306(5695): p. 457-461. 
144. Szegezdi, E., et al., Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO 
reports, 2006. 7(9): p. 880-885. 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
24 
 
145. Shimizu, S., et al., DPP4 inhibitor vildagliptin preserves-cell mass through amelioration of 
endoplasmic reticulum stress in C/EBPB transgenic mice. Journal of molecular endocrinology, 
2012. 49(2): p. 125. 
146. Ramracheya, R., et al., GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells 
by inhibition of P/Q-type Ca2+ channels. Physiological reports, 2018. 6(17): p. e13852. 
147. Færch, K., et al., Insulin resistance is accompanied by increased fasting glucagon and delayed 
glucagon suppression in individuals with normal and impaired glucose regulation. Diabetes, 
2016. 65(11): p. 3473-3481. 
148. Katayama, T., et al., The Activation of Glucagon-Like Peptide-1 Improves the Mitochondrial 
Abnormalities in Skeletal Muscle and Exercise Intolerance in Heart Failure Mice. Journal of 
Cardiac Failure, 2016. 22(9): p. S162. 
 
©2019, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
